BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38168914)

  • 41. Long non-coding RNA TRIM52-AS1 sponges microRNA-577 to facilitate diffuse large B cell lymphoma progression via increasing TRIM52 expression.
    Zhao F; Li S; Liu J; Wang J; Yang B
    Hum Cell; 2022 Jul; 35(4):1234-1247. PubMed ID: 35676608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of chidamide on human B lymphoma cell lines and its mechanisms].
    Li YY; Wang YF; Wang J; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):893-9. PubMed ID: 22931650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C; Chen Z; Li Y
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis.
    Hu L; Zhao J; Liu Y; Liu X; Lu Q; Zeng Z; Zhu L; Tong X; Xu Q
    Int J Med Sci; 2020; 17(17):2735-2743. PubMed ID: 33162801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
    Yuan XG; Huang YR; Yu T; Jiang HW; Xu Y; Zhao XY
    Oncol Lett; 2019 Jul; 18(1):411-419. PubMed ID: 31289512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
    Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
    Zhu F; Crombie JL; Ni W; Hoang NM; Garg S; Hackett L; Chong SJF; Collins MC; Rui L; Griffin J; Davids MS
    Haematologica; 2024 Jan; 109(1):186-199. PubMed ID: 37534528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
    Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
    Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.
    Wang X; Wang D; Ding N; Mi L; Yu H; Wu M; Feng F; Hu L; Zhang Y; Zhong C; Ye Y; Li J; Fang W; Shi Y; Deng L; Ying Z; Song Y; Zhu J
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-cell profiling-guided combination therapy of c-Fos and histone deacetylase inhibitors in diffuse large B-cell lymphoma.
    Wang L; Wu Z; Xia Y; Lu X; Li J; Fan L; Qiao C; Qiu H; Gu D; Xu W; Li J; Jin H
    Clin Transl Med; 2022 May; 12(5):e798. PubMed ID: 35522945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MiR-645 regulates the proliferation and apoptosis of diffuse large B-cell lymphoma by targeting DACH1.
    Wang R; Shen J; Su N; Wang Q; Zhang M; Liu C
    Hum Cell; 2020 Oct; 33(4):1091-1098. PubMed ID: 32529465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma.
    Ge X; Lv X; Feng L; Liu X; Gao J; Chen N; Wang X
    PLoS One; 2012; 7(6):e39449. PubMed ID: 22768080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway.
    Gao G; Xue Q; He J; Wu M; Jiang Y; Li Q; Zhang Y; Shi W
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111125. PubMed ID: 37907047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma.
    Li Q; Li B; Lu CL; Wang JY; Gao M; Gao W
    Cancer Gene Ther; 2021 Sep; 28(9):1046-1057. PubMed ID: 33311569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.